Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137371 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
NCT00137371 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 480 participants.
The verdict
NCT00137371, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
Study Summary
This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.
Interventions
- DRUG PVC (daily for 21 days, 7 days off)
- DRUG PVC (twice weekly)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137371
The ClinicalTrials.gov registry entry for NCT00137371 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PVC (daily for 21 days, 7 days off) is the first listed.
NCT00137371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00137371 about?
NCT00137371 is a clinical study titled "Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis". This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.
What is the current status of trial NCT00137371?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2005-08. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00137371?
The interventions under investigation include: PVC (daily for 21 days, 7 days off) (DRUG), PVC (twice weekly) (DRUG).
Who is sponsoring clinical trial NCT00137371?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.